AB057. Intravesicular administration of sodium hyaluronate ameliorates the inflammation and cell proliferation of cystitis cystica et glandularis involving interleukin-6/Stat3 signaling pathway

Background: In this study, we evaluate the clinical use of intravesical sodium hyaluronate in Cystitis cystica et glandularis (CCEG) patients who have completed treatment and investigate the role of the IL-6/Stat3 pathway in CCEG and examine the effect of SH on this pathway.

Methods: Patients and model rats received intravesical sodium hyaluronate. Cystoscopy was performed before and after intravesicular therapy. After the experiments, bladder tissues were excised for histological examination, and the measurements of IL6/Stat3 pathway activities.

Results: Intravesicular SH treatment significantly mitigated the bladder mucosal inflammation and proliferation characteristic, clinical symptoms and decreased IL-6 and p-Stat3 expression of CCEG. HYAL 1/2 and CD44 expression levels, CD44-dependent IL-6/Stat3 pathway activation.

Conclusions: Intravesical SH therapy significantly improved the clinical symptoms of patients with CCEG and ameliorated the bladder mucosal inflammation and cell proliferation characteristic of the disease involving IL-6/Stat3 pathway.

Keywords: Intravesical; sodium hyaluronan; IL-6; Stat3